文献速递糖尿病

口服胰岛素延迟3期1型糖尿病:TN07试验中HLA DR4-DQ8参与者的再分析

Oral Insulin Delay of Stage 3 Type 1 Diabetes Revisited in HLA DR4-DQ8 Participants in the TrialNet Oral Insulin Prevention Trial (TN07).
PubMed 文献 · Diabetes Care · 2024-01-01

本研究对TrialNet口服胰岛素预防试验(TN07)中546例1/2期1型糖尿病患者进行HLA分型和自身抗体检测,事后分析显示口服胰岛素在IA-2A高水平的受试者中降低3期1型糖尿病发病频率(HR 0.62;P=0.012),在HLA DR4-DQ8携带者中延缓进展至3期1型糖尿病(HR 0.59;P=0.027)。

要点

  • 口服胰岛素在IA-2A高水平的1/2期1型糖尿病患者中降低3期发病频率(HR 0.62;P=0.012)。
  • 口服胰岛素在HLA DR4-DQ8携带者中延缓进展至3期1型糖尿病(HR 0.59;P=0.027)。
  • IA-2A高水平与HLA DR4-DQ8单倍型正相关(OR 1.63;P=6.37×10⁻⁶)。

核心结论

  • 结果提示存在以HLA DR4-DQ8和/或IA-2A水平升高为特征的1型糖尿病内表型,对于具有该内表型的1/2期患者,口服胰岛素可延迟临床1型糖尿病发病。

研究设计与样本

  • 对TrialNet口服胰岛素预防试验(TN07)中546例参与者进行事后分析,采用下一代靶向测序技术对8个HLA II类基因(DQA1、DQB1、DRB1、DRB3、DRB4、DRB5、DPA1和DPB1)进行基因分型。
  • 在治疗分组前测定胰岛素自身抗体(IAA)、GAD65自身抗体(GADA)和IA-2自身抗体(IA-2A)的基线水平,利用TN07可获得的临床和人口学协变量,采用Cox回归模型量化口服胰岛素的预防效果。

主要发现

  • 口服胰岛素在IA-2A水平升高的参与者中降低1型糖尿病发病频率(HR 0.62;P=0.012),但在IA-2A水平低的参与者中无预防效果(HR 1.03;P=0.91)。
  • IA-2A高水平与HLA DR4-DQ8单倍型正相关(OR 1.63;P=6.37×10⁻⁶),与含HLA DR7的DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02扩展单倍型负相关(OR 0.49;P=0.037)。
  • 在DR4-DQ8携带者中,口服胰岛素延缓向3期1型糖尿病发病的进展(HR 0.59;P=0.027),尤其在同时具有高IA-2A水平的参与者中(HR 0.50;P=0.028)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore if oral insulin could delay onset of stage 3 type 1 diabetes (T1D) among patients with stage 1/2 who carry HLA DR4-DQ8 and/or have elevated levels of IA-2 autoantibodies (IA-2As). RESEARCH AND METHODS: Next-generation targeted sequencing technology was used to genotype eight HLA class II genes (DQA1, DQB1, DRB1, DRB3, DRB4, DRB5, DPA1, and DPB1) in 546 participants in the TrialNet oral insulin preventative trial (TN07). Baseline levels of autoantibodies against insulin (IAA), GAD65 (GADA), and IA-2A were determined prior to treatment assignment. Available clinical and demographic covariables from TN07 were used in this post hoc analysis with the Cox regression model to quantify the preventive efficacy of oral insulin. RESULTS: Oral insulin reduced the frequency of T1D onset among participants with elevated IA-2A levels (HR 0.62; P = 0.012) but had no preventive effect among those with low IA-2A levels (HR 1.03; P = 0.91). High IA-2A levels were positively associated with the HLA DR4-DQ8 haplotype (OR 1.63; P = 6.37 × 10-6) and negatively associated with the HLA DR7-containing DRB1*07:01-DRB4*01:01-DQA1*02:01-DQB1*02:02 extended haplotype (OR 0.49; P = 0.037). Among DR4-DQ8 carriers, oral insulin delayed the progression toward stage 3 T1D onset (HR 0.59; P = 0.027), especially if participants also had high IA-2A level (HR 0.50; P = 0.028). CONCLUSIONS: These results suggest the presence of a T1D endotype characterized by HLA DR4-DQ8 and/or elevated IA-2A levels; for those patients with stage 1/2 disease with such an endotype, oral insulin delays the clinical T1D onset.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Zhao LP, Papadopoulos GK, Skyler JS, et al. Oral Insulin Delay of Stage 3 Type 1 Diabetes Revisited in HLA DR4-DQ8 Participants in the TrialNet Oral Insulin Prevention Trial (TN07). Diabetes Care. 2024. PMID: 38949847. doi:10.2337/dc24-0573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。